Shares in this article
by Georg Pröbstl, Euro am Sonntag
D.he knot burst! After much preparatory work, there is now momentum in the commercialization of Magforce’s therapy against brain tumors, specifically against the aggressive variant glioblastoma. Since the first half of the year, more and more surgeons in Europe have been using this treatment method. Company boss Ben Lipps is confident. The number of treatments is expected to triple over the next year. Well-informed circles even report significantly higher growth rates.
Magforce uses magnetic nanoparticles for his therapy. These are heated by an alternating magnetic field and destroy or weaken the cancer cells so that chemotherapy works better with fewer side effects. Magforce sees itself as the only provider in the world with the process and is working on European-wide market penetration. Treatment centers are planned for next year in Italy, Spain and Germany. Manager Lipps has also declared war on prostate cancer. The medical company uses many therapy components against brain tumors for this. In the USA, the approval process by the US health authority FDA is well advanced, and additional treatment centers will start operating in December.
Well-informed circles are expecting January with positive news from the USA. There is a billion dollar market for both healing methods. After Magforce has completed the preparatory work, stockbrokers expect a sales explosion. In four to five years, revenues are expected to increase from 1.0 to 100 million euros. Since, according to well-informed circles, Magforce wants to go public in the US in the first half of the year – there are far higher prices for such shares – prices of seven to eight euros are conceivable next year.
Risky investors rely on
News in January and speculate
on going public in the US
in May or June.
ISIN: DE 000 A0H GQF 5
Weight / share 2022e: € 0.01
PER 2022 / dividend: 410.0 / –
EK * per share / KBV: € 0.35 / 11.7
Equity ratio: 24.9%
Course / target / stop: 4.15 / 6.80 / 2.40 €
More news about MagForce AG
Image sources: Tang Yan Song / Shutterstock.com, pupunkkop / Shutterstock.com